US Pharma MarketingEuropean Commission approves Novartis’ Itvisma to treat SMA
The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene. The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies. Itvisma works by providing a functional copy of the SMN1 gene, which is deficient in people with SMA. Credit: Andrzej Rostek/Shutterstock.com. The European Commission has granted approval for Novartis’ Itvisma (onasemnogene abeparvovec) as a treatment for children two years and older, teenagers and adults who have 5q spinal muscular atrophy (SMA)…
The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.
Source: Pharmaceutical Technology